BeOne Medicines (ONC) SVP & General Counsel reports option exercises and ADS sale

Rhea-AI Filing Summary

BeOne Medicines Ltd. insider Lee Chan Henry, SVP and General Counsel, reported option exercises and an automatic sale of American Depositary Shares (ADS). On January 7, 2026, Henry exercised three share options covering 2,626, 3,458 and 2,548 Ordinary Shares at exercise prices of $14.96, $16.41 and $12.23 per Ordinary Share. These exercises resulted in issuances of 202, 266 and 196 ADS at prices of $194.47, $213.32 and $159.03 per ADS. The filing also reports a sale of 664 ADS at $331.76 per ADS, carried out under a Rule 10b5-1 trading plan adopted on May 14, 2025. After these transactions, Henry reported 223,106 Ordinary Shares beneficially owned directly and continued holdings of multiple option grants with staggered vesting schedules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								223,106	D
American Depositary Shares(1)	01/07/2026		M		202	A	$194.47	202	D
American Depositary Shares(1)	01/07/2026		M		266	A	$213.32	468	D
American Depositary Shares(1)	01/07/2026		M		196	A	$159.03	664	D
American Depositary Shares(1)	01/07/2026		S(2)		664	D	$331.76	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(3)	01/07/2026		M			2,626	(4)	08/04/2032	Ordinary Shares	2,626	$0	30,446	D
Share Option (Right to Buy)	$16.41(3)	01/07/2026		M			3,458	(5)	06/14/2033	Ordinary Shares	3,458	$0	97,019	D
Share Option (Right to Buy)	$12.23(3)	01/07/2026		M			2,548	(6)	06/04/2034	Ordinary Shares	2,548	$0	118,118	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in BeOne Medicines (ONC) Form 4 and what is their role?

The Form 4 reports transactions by Lee Chan Henry, who serves as SVP, General Counsel of BeOne Medicines Ltd. and is an officer but not a director or 10% owner.

What share option exercises did Lee Chan Henry report for BeOne Medicines (ONC)?

On January 7, 2026, Henry exercised three Share Option (Right to Buy) grants for 2,626, 3,458 and 2,548 Ordinary Shares with exercise prices of $14.96, $16.41 and $12.23 per Ordinary Share.

How many American Depositary Shares did the BeOne Medicines (ONC) insider sell and at what price?

The filing shows a sale of 664 American Depositary Shares at a price of $331.76 per ADS, reported with transaction code S.

Were the BeOne Medicines (ONC) insider sales under a Rule 10b5-1 trading plan?

Yes. A footnote states that the sale of ADS was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.

What BeOne Medicines (ONC) shareholdings does the insider report after the transactions?

After the reported transactions, the Form 4 shows 223,106 Ordinary Shares beneficially owned directly, along with remaining option positions including 30,446, 97,019 and 118,118 derivative securities reported as directly owned.

How are BeOne Medicines (ONC) American Depositary Shares related to Ordinary Shares?

A footnote explains that each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines Ltd.